Literature DB >> 24584620

32 years' experience of peritoneal dialysis-related peritonitis in a university hospital.

Sadie van Esch1, Raymond T Krediet, Dirk G Struijk.   

Abstract

BACKGROUND: Peritonitis in peritoneal dialysis (PD) patients can lead to technique failure and contributes to infection-related mortality. Peritonitis prevention and optimization of treatment are therefore important in the care for PD patients. In the present study, we analyzed the incidence of peritonitis, causative pathogens, clinical outcomes, and trends in relation to three major treatment changes that occurred from 1979 onward: use of a disconnect system since 1988, daily mupirocin at the exit-site since 2001, and exclusive use of biocompatible dialysis solutions since 2004.
METHODS: In this analysis of prospectively collected data, we included peritonitis episodes from the start of PD at our center in August 1979 to July 2010. Incident PD patients were allocated to one of four groups: Group 1 - 182 patients experiencing 148 first peritonitis episodes between 1979 and 1987, before the introduction of the disconnect system; Group 2 - 352 patients experiencing 239 first episodes of peritonitis between 1988 and 2000, before implementation of daily mupirocin application at the catheter exit-site; Group 3 - 79 patients experiencing 50 first peritonitis episodes between 2001 and 2003, before the switch to biocompatible solutions; and Group 4-118 patients experiencing 91 first peritonitis episodes after 2004. Cephradine was used as initial antibiotic treatment.
RESULTS: In 32 years, 731 adult patients started PD, and 2234 episodes of peritonitis in total were diagnosed and treated. Of those episodes, 88% were cured with medical treatment only, and 10% resulted in catheter removal. In 3% of the episodes, the patient died during peritonitis. Median time to a first peritonitis episode increased from 40 days for group 1 to 150 for group 2, 269 for group 3, and 274 for group 4. The overall peritonitis rate and the gram-positive and gram-negative peritonitis rates showed a time-trend of decline. However, the duration of antibiotic treatment increased over time, with groups 3 and 4 having the longest duration of treatment, accompanied by a higher percentage of antibiotic switch. Increased resistance to cephradine was found for coagulase-negative Staphylococcus.
CONCLUSIONS: Peritonitis rates declined significantly over the years because of several changes in PD treatment. However, the need to change the initial antibiotic increased because of diminished antibiotic susceptibility rates over time. Nevertheless, the cure rate was high and remained stable during the entire period analyzed, and the death rate remained low. Consequently, peritonitis is a manageable complication of PD that cannot be considered a contraindication to this mode of renal replacement therapy.

Entities:  

Keywords:  Infection; peritonitis; peritonitis outcomes

Mesh:

Substances:

Year:  2014        PMID: 24584620      PMCID: PMC3968101          DOI: 10.3747/pdi.2013.00275

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  33 in total

1.  Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade.

Authors:  Dong Ki Kim; Tae-Hyun Yoo; Dong-Ryeol Ryu; Zhong-Gao Xu; Hyun Jin Kim; Kyu Hun Choi; Ho Yung Lee; Dae-Suk Han; Shin-Wook Kang
Journal:  Perit Dial Int       Date:  2004 Sep-Oct       Impact factor: 1.756

Review 2.  Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients.

Authors:  G F M Strippoli; A Tong; D Johnson; F P Schena; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

3.  Clinical efficacy and morbidity associated with continuous cyclic compared with continuous ambulatory peritoneal dialysis.

Authors:  C W de Fijter; L P Oe; J J Nauta; J van der Meulen; H A Verbrugh; J Verhoef; A J Donker
Journal:  Ann Intern Med       Date:  1994-02-15       Impact factor: 25.391

4.  Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: a single centre Indian experience.

Authors:  K N Prasad; N Prasad; A Gupta; R K Sharma; A K Verma; A Ayyagari
Journal:  J Infect       Date:  2004-01       Impact factor: 6.072

5.  Antifungal treatment of Candida peritonitis in continuous ambulatory peritoneal dialysis patients.

Authors:  D G Struijk; R T Krediet; E W Boeschoten; P J Rietra; L Arisz
Journal:  Am J Kidney Dis       Date:  1987-01       Impact factor: 8.860

6.  Infecting organisms in continuous ambulatory peritoneal dialysis patients on the Y-set.

Authors:  J L Holley; J Bernardini; B Piraino
Journal:  Am J Kidney Dis       Date:  1994-04       Impact factor: 8.860

7.  Peritonitis in an urban peritoneal dialysis program: an analysis of infecting pathogens.

Authors:  S M Korbet; E F Vonesh; C A Firanek
Journal:  Am J Kidney Dis       Date:  1995-07       Impact factor: 8.860

8.  A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: is empiric vancomycin still indicated for some patients?

Authors:  George W Kan; Mark A B Thomas; Christopher H Heath
Journal:  Perit Dial Int       Date:  2003 Sep-Oct       Impact factor: 1.756

9.  Peritoneal dialysis-associated peritonitis in Scotland (1999-2002).

Authors:  David Kavanagh; Gordon J Prescott; Robert A Mactier
Journal:  Nephrol Dial Transplant       Date:  2004-08-10       Impact factor: 5.992

10.  CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine.

Authors:  E W Boeschoten; P J Rietra; R T Krediet; M J Visser; L Arisz
Journal:  J Antimicrob Chemother       Date:  1985-12       Impact factor: 5.790

View more
  18 in total

1.  The Application Analysis of Multiplex Real-Time Polymerase Chain Reaction Assays for Detection of Pathogenic Bacterium in Peritoneal Dialysis-Associated Peritonitis.

Authors:  Jing Yang; Xiang-Ming Qi; Yong-Gui Wu
Journal:  Blood Purif       Date:  2019-01-02       Impact factor: 2.614

2.  Peritonitis rates of the past thirty years: from improvement to stagnation.

Authors:  Cheuk-Chun Szeto
Journal:  Perit Dial Int       Date:  2014 Mar-Apr       Impact factor: 1.756

Review 3.  A contemporary approach to the prevention of peritoneal dialysis-related peritonitis in children: the role of improvement science.

Authors:  Allison Redpath Mahon; Alicia M Neu
Journal:  Pediatr Nephrol       Date:  2016-10-18       Impact factor: 3.714

4.  The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis.

Authors:  M Kussmann; L Schuster; M Zeitlinger; P Pichler; G Reznicek; M Wiesholzer; H Burgmann; W Poeppl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-04       Impact factor: 3.267

5.  Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.

Authors:  Manuel Kussmann; Linda Schuster; Sarah Wrenger; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Perit Dial Int       Date:  2016-09-28       Impact factor: 1.756

6.  Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program.

Authors:  Shan Shan Chen; Heena Sheth; Beth Piraino; Filitsa Bender
Journal:  Perit Dial Int       Date:  2015-12-03       Impact factor: 1.756

7.  The Association Between Glucose Exposure and the Risk of Peritonitis in Peritoneal Dialysis Patients.

Authors:  Anouk T N van Diepen; Sadie van Esch; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2016-04-04       Impact factor: 1.756

8.  Microbiological Surveillance of Peritoneal Dialysis Associated Peritonitis: Antimicrobial Susceptibility Profiles of a Referral Center in GERMANY over 32 Years.

Authors:  Daniel Kitterer; Joerg Latus; Christoph Pöhlmann; M Dominik Alscher; Martin Kimmel
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

Review 9.  Evaluating the benefits of home-based peritoneal dialysis.

Authors:  Karlien François; Joanne M Bargman
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-12-04

10.  Deciphering the Contribution of Biofilm to the Pathogenesis of Peritoneal Dialysis Infections: Characterization and Microbial Behaviour on Dialysis Fluids.

Authors:  Joana Sampaio; Diana Machado; Ana Marta Gomes; Idalina Machado; Cledir Santos; Nelson Lima; Maria João Carvalho; António Cabrita; Anabela Rodrigues; Margarida Martins
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.